Related Experiment Video
Updated: Sep 28, 2026

A Modified Inflammatory Pain Model to Study the Analgesic Effect in Mice
Published on: November 15, 2024
Comparison of receptor mechanisms and efficacy requirements for delta-agonist-induced convulsive activity and
Daniel C Broom1, Joshua F Nitsche, John E Pintar
1Department of Pharmacology, University of Michigan Medical School, 1150 West Medical Center Drive, Ann Arbor, MI 48109-0632, USA.
Abstract:
Delta-opioid receptor-selective agonists produce antinociception and convulsions in several species, including mice. This article examines two hypotheses in mice: 1) that antinociception and convulsive activity are mediated through the same type of delta-receptor and 2) that greater delta-agonist efficacy is required for antinociception than for convulsive activity. Delta-mediated antinociception was evaluated in the acetic acid-induced abdominal constriction assay, which involves a low-intensity noxious stimulus; convulsive activity was indicated as a mild tonic-clonic convulsive episode followed by a period of catalepsy. In delta-opioid receptor knockout mice [DOR-1(-/-)], the nonpeptidic delta-agonists (+/-)-4-[(R*)-[(2S*,5R*)-2,5-dimethyl-4-(2-propenyl)-1- piperazinyl]-(3-hydroxyphenyl)methyl]-N,N-diethylbenzamide hydrochloride (BW373U86) and (+)-4-[(R)-[(2S,5R)-2,5-dimethyl-4-(2-propenyl)-1-piperazinyl]-(3-methoxyphenyl)methyl]-N, N-diethylbenzamide (SNC80) failed to produce convulsive behavior demonstrating the absolute involvement of DOR-1 in this effect. In NIH Swiss mice expressing delta-opioid receptors, BW373U86 produced both antinociception and convulsive activity. These effects were antagonized by the putative delta(1)-receptor-selective antagonist 7-benzylidenenaltrexone and the putative delta(2)-receptor-selective antagonist naltriben. Tolerance developed to both the convulsive and antinociceptive effects of BW373U86. Tolerance to the convulsive, but not the antinociceptive, effects of BW373U86 was largely prevented when the antagonist naltrindole was given 20 min after each dose of the agonist in a 3-day treatment paradigm. The convulsive action of BW373U86 was also less sensitive than the antinociceptive action to treatment with the irreversible delta-antagonist naltrindole isothiocyanate. Collectively, these data suggest that the convulsive and antinociceptive activities of delta-agonists are mediated through the same receptor but that the receptor reserve for delta-mediated convulsive activity is greater than for delta-mediated antinociceptive activity.
Insights
Delta-opioid receptor agonists cause pain relief and seizures. This study suggests both effects stem from the same delta-opioid receptor (DOR-1), but seizures require a higher agonist efficacy, indicating a larger receptor reserve for this effect.
Area of Science:
- Neuroscience
- Pharmacology
Background:
- Delta-opioid receptor (DOR) agonists are known to produce antinociception and convulsions.
- The precise mechanisms and receptor subtypes involved in these distinct effects remain under investigation.
Purpose of the Study:
- To investigate whether antinociception and convulsive activity are mediated by the same DOR subtype.
- To determine if greater delta-agonist efficacy is required for antinociception compared to convulsive activity.
Main Methods:
- Utilized delta-opioid receptor knockout mice (DOR-1(-/-)) and wild-type mice.
- Administered nonpeptidic delta-agonists (BW373U86, SNC80) and assessed antinociception (acetic acid assay) and convulsive behavior.
- Employed selective DOR antagonists (7-benzylidenenaltrexone, naltriben, naltrindole) and an irreversible antagonist (naltrindole isothiocyanate) to probe receptor involvement and tolerance.
Main Results:
- BW373U86 and SNC80 failed to induce convulsions in DOR-1(-/-) mice, confirming DOR-1's essential role.
- In wild-type mice, BW373U86 produced both antinociception and convulsions, which were antagonized by selective DOR antagonists.
- Tolerance developed to both effects, but the convulsive effect showed less tolerance development compared to antinociception, suggesting a greater receptor reserve for convulsions.
Conclusions:
- Both antinociceptive and convulsive activities of delta-opioid agonists are mediated by the same receptor (DOR-1).
- A greater receptor reserve exists for delta-mediated convulsive activity compared to delta-mediated antinociceptive activity.
- These findings contribute to understanding the differential signaling and efficacy requirements of DOR-1 activation.
Related Concept Videos
Opioid Receptors: Overview
Analgesia and Pain Management

